Ascletis Reports Patients Dosing in Multiple-Dose Escalation P-I Clinical Trial of ASC10 for COVID-19
Shots:
- The company reported the dosing of 24 healthy patients from the first 3 cohorts in a multiple-dose escalation P-I trial to evaluate ASC10 for COVID-19
- Additionally, 72 healthy patients incl. 60 with multiple doses of ASC10 (50/100/200/400/600/800mg, BID) vs PBO for 5.5 days in 6 dose-escalation cohorts while 12 received two single 800mg doses to evaluate the food effect on PK of ASC10, will be enrolled in the trial
- In the SARS-CoV-2 infected mouse models, ASC10 at 240mg/kg, BID showed a 4.0 log reduction in viral titer in the lungs, equivalent to molnupiravir at 500mg/kg, BID. The recent study showed that ASC10-A remains effective against variant BA.5 and the emerging variant BA.2.75
Ref: PRNewswire | Image: Ascletis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
